Approved Biospecimen Research

View a listing of Washington University investigators (pdf) who are approved to conduct COVID-19 research with biospecimens. This roster will be updated regularly as new studies are approved.

Listen to a recording (WUSTL key required) of the June 2, 2020 meeting with current COVID-19 biospecimen users to discuss research plans and sharing of clinical and experimental data.

Approved protocols for COVID-19 biospecimen collection at Washington University are outlined below.

Name/TitleDescriptionSamples collectedClinical data
WU350(IRB#202003085)

Immunological, genetics and clinical predictors of SARS CoV-2 infection
ED and inpatient based recruitment, with samples collected at up to 6 time points (0,3,7,14,28,84). Follow-up outpatient in ID clinic
(Goal recruitment=300)
Plasma
Serum
PaxGene
Cryopreserved Cells
Urine
Saliva

Location: Tissue Procurement Core
REDCap and I2 DataCommons
WU353(IRB# 202003186)

Registry and screening of participants with history of confirmed SARS CoV-2 infection to evaluate for eligibility for donation of convalescent plasma
Donor plasma protocol, single time point (Goal=5/d)Plasma
Serum
Cryopreserved Cells

Location: Tissue Procurement Core
REDCap and I2 DataCommons
OB/GYN(IRB# 202003130)

Course of COVID-19 Infection in Pregnancy
Inpatient and outpatient collection from pregnant women and infantsBlood
Saliva
NP swabs
Urine
amniotic fluid

Locations: WIHSC
REDCap

Process for Obtaining Biospecimens

View an overview of the process for obtaining biospecimens for COVID-19 research at Washington University (pdf).